Cited by 213Myeloproliferative Neoplasms: Diagnosis and TreatmentPlatelet Disorders and TreatmentsAcute Myeloid Leukemia Research

Pivotal contributions of megakaryocytes to the biology of idiopathic myelofibrosis

Open access
Ciurea, Stefan O., Merchant, Delwin, Mahmud, Nadim, Ishii, Takefumi, Zhao, Yan, Hu, Wenyang, Bruno, Edward, Barosi, Giovanni +2 more·2007·Blood

Abstract

In order to investigate the biologic processes underlying and resulting from the megakaryocytic hyperplasia that characterizes idiopathic myelofibrosis (IMF), peripheral blood CD34+ cells isolated from patients with IMF, polycythemia vera (PV), and G-CSF–mobilized healthy volunteers were cultured in the presence of stem cell factor and thrombopoietin. IMF CD34+ cells generated 24-fold greater numbers of megakaryocytes (MKs) than normal CD34+ cells. IMF MKs were also shown to have a delayed pattern of apoptosis and to overexpress the antiapoptotic protein bcl-xL. MK hyperplasia in IMF is, therefore, likely a consequence of both the increased ability of IMF progenitor cells to generate MKs and a decreased rate of MK apoptosis. Media conditioned (CM) by CD61+ cells generated in vitro from CD34+ cells were then assayed for the levels of growth factors and proteases. Higher levels of transforming growth factor-β (TGF-β) and active matrix metalloproteinase-9 (MMP9) were observed in media conditioned with IMF CD61+ cells than normal or PV CD61+ cells. Both normal and IMF CD61+ cells produced similar levels of VEGF. MK-derived TGF-B and MMP-9, therefore, likely contribute to the development of many pathological epiphenomena associated with IMF.

Integrity signals

Registry

Crossref · 10.1182/blood-2006-12-064626

Cites

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • CD9 and VWF are closely associated with MkP differentiation.

    “In the MkPs, we identified a downregulation of CD9 and VWF , closely associated with MkP differentiation 46-49 , upon IFNa treatment ( Supplementary Fig. 4b ) which is consistent with the decrease in the proportion of MkP observed after IFNa treatment.”
  • In MkPs, CD9 and VWF were downregulated upon IFNa treatment.

    “In the MkPs, we identified a downregulation of CD9 and VWF , closely associated with MkP differentiation 46-49 , upon IFNa treatment ( Supplementary Fig. 4b ) which is consistent with the decrease in the proportion of MkP observed after IFNa treatment.”

Cited by

Sorted by citations

Authors
Ciurea, S. O., Merchant, D., Mahmud, N., Ishii, T., Zhao, Y., Hu, W., Bruno, E., Barosi, G., Xu, M., & Hoffman, R.
Affiliations
  • University of Illinois Chicago (US)
  • University of Illinois College of Medicine at Chicago, Hematology/Oncology Section, Department of Medicine, Chicago;
  • Policlinico San Matteo Fondazione (IT)
Venue
Blood
Published
2007-08-01
Volume
110
Issue
3
Pages
986-993
ISSN
  • 0006-4971 (ISSN-L)
  • 1528-0020
OpenAlex
W2052033797
Cited by
213
References
0
Citations by year
2026: 6 · 2025: 10 · 2024: 10 · 2023: 11 · 2022: 19 · 2021: 15 · 2020: 14 · 2019: 16 · 2018: 11 · 2017: 15 · 2016: 11 · 2015: 10 · 2014: 6 · 2013: 10 · 2012: 9
FWCI
4.56
Type
journal article
Language
en
Open access
Locations
  • Blood (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • University of Illinois at Urbana-Champaign
  • National Cancer Institute (P01CA108671)
Topics
  • Health Sciences › Medicine › Genetics › Myeloproliferative Neoplasms: Diagnosis and Treatment
  • Health Sciences › Medicine › Hematology › Platelet Disorders and Treatments
  • Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
Keywords
primary myelofibrosis, megakaryocytes, megakaryocytic hyperplasia, CD34+ cells, apoptosis, Bcl-xL, polycythemia vera, stem cell factor, thrombopoietin, TGF-beta, MMP-9, vascular endothelial growth factor
MeSH terms
Adult, Aged, Cells, Cultured, Female, Hematopoietic Stem Cells, Humans, Hyperplasia, Male, Megakaryocytes, Middle Aged, Polycythemia Vera, Thrombopoietin, Granulocyte Colony-Stimulating Factor, Transforming Growth Factor beta, Culture Media, Conditioned, Apoptosis, Antigens, CD34, Hematopoietic Stem Cell Mobilization, Matrix Metalloproteinase 9, Integrin beta3, Vascular Endothelial Growth Factor A, bcl-X Protein, Primary Myelofibrosis

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review